The HSP90 inhibitor Onalespib exerts synergistic anti-cancer effects when combined with radiotherapy: an in vitro and in vivo approach

Oncogenic client-proteins of the chaperone Heat shock protein 90 (HSP90) insure unlimited tumor growth and are involved in resistance to chemo- and radiotherapy. The HSP90 inhibitor Onalespib initiates the degradation of oncoproteins, and might also act as a radiosensitizer. The aim of this study wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Spiegelberg, Diana, Abramenkovs, Andris, Mortensen, Anja Charlotte Lundgren, Lundsten, Sara, Nestor, Marika, Stenerlöw, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125222/
https://www.ncbi.nlm.nih.gov/pubmed/32246062
http://dx.doi.org/10.1038/s41598-020-62293-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125222/
https://www.ncbi.nlm.nih.gov/pubmed/32246062
http://dx.doi.org/10.1038/s41598-020-62293-4

Ejemplares similares